Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: hedgehog cell-signalling pathway inhibitors - Infinity

Drug Profile

Research programme: hedgehog cell-signalling pathway inhibitors - Infinity

Alternative Names: IPI-269609; IPI-609

Latest Information Update: 11 Mar 2013

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Infinity Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Hedgehog cell-signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 11 Mar 2013 Discontinued - Preclinical for Cancer in USA (PO)
  • 14 Dec 2010 Infinity Pharmaceuticals and Mundipharma expand their strategic alliance agreement
  • 04 Nov 2010 Infinity Pharmaceuticals receives three grants under the US Government's Qualifying Therapeutic Discovery Project Programme to advance its three research programmes, including hedgehog pathway inhibitors
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top